ISDA

Deposition Date 2022-06-02

Release Date 2022-10-19

Last Version Date 2024-01-31

Entry Detail

PDB ID:

8A27

Keywords:

TRANSFERASE

Title:

EGFR kinase domain in complex with 2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-1-yl)-2-[6-[2-[4-[[4-(hydroxymethyl)-1-piperidyl]methyl]phenyl]ethynyl]-1-oxo-4-(trifluoromethyl)isoindolin-2-yl]-N-thiazol-2-yl-acetamide

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.07 Å

R-Value Free:

0.15

R-Value Work:

0.12

R-Value Observed:

0.12

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Epidermal growth factor receptor
Gene (Uniprot):EGFR
Chain IDs:A
Chain Length:326
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P00533 Pfam ID:PF07714 EC:2.7.10.1

Ligand Molecules

EDO

KY9

NO3

Primary Citation

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.

Obst-Sander, U, Ricci, A, Kuhn, B, Friess, T, Koldewey, P, Kuglstatter, A, Hewings, D, Goergler, A, Steiner, S, Rueher, D, Imhoff, M.P, Raschetti, N, Marty, H.P, Dietzig, A, Rynn, C, Ehler, A, Burger, D, Kornacker, M, Schaffland, J.P, Herting, F, Pao, W, Bischoff, J.R, Martoglio, B, Alice Nagel, Y, Jaeschke, G.Show

J.Med.Chem. 65 13052 13073 (2022)

PMID: 36178776 DOI: 10.1021/acs.jmedchem.2c00893

Abstact

Addressing resistance to third-generation EGFR TKIs such as osimertinib via the EGFRC797S mutation remains a highly unmet need in EGFR-driven non-small-cell lung cancer (NSCLC). Herein, we present the discovery of the allosteric EGFR inhibitor 57, a novel fourth-generation inhibitor to overcome EGFRC797S-mediated resistance in patients harboring the activating EGFRL858R mutation. 57 exhibits an improved potency compared to previous allosteric EGFR inhibitors. To our knowledge, 57 is the first allosteric EGFR inhibitor that demonstrates robust tumor regression in a mutant EGFRL858R/C797S tumor model. Additionally, 57 is active in an H1975 EGFRL858R/T790M NSCLC xenograft model and shows superior efficacy in combination with osimertinib compared to the single agents. Our data highlight the potential of 57 as a single agent against EGFRL858R/C797S and EGFRL858R/T790M/C797S and as combination therapy for EGFRL858R- and EGFRL858R/T790M-driven NSCLC.

Legend

Protein

Chemical

Disease

Primary Citation of related structures